DNTH Valuation

Dianthus Therapeutics Inc

Add to Watchlist

Advanced Chart

21.700

0.000(0.000%)

Overview
Forecast
Valuation

DNTH Relative Valuation

DNTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNTH is overvalued; if below, it's undervalued.

Historical Valuation

Dianthus Therapeutics Inc (DNTH) is now in the Fair zone, suggesting that its current forward PS ratio of 199.70 is considered Fairly compared with the five-year average of 270.42. The fair price of Dianthus Therapeutics Inc (DNTH) is between 12.26 to 40.48 according to relative valuation methord.

Relative Value

Fair Zone

12.26-40.48

Current Price：21.70

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.92

P/B

Median3y

1.75

Median5y

1.75

-11.15

FCF Yield

Median3y

-10.45

Median5y

-10.45

Competitors Valuation Multiple

The average P/S ratio for DNTH's competitors is 114.57, providing a benchmark for relative valuation. Dianthus Therapeutics Inc Corp (DNTH) exhibits a P/S ratio of 199.70, which is 74.30% above the industry average. Given its robust revenue growth of 190.15%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DNTH.O

Dianthus Therapeutics Inc

199.70

Average P/S: 114.57

190.15%